Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung cancer (NSCLC), typically in female individuals, who are non-smokers, and have ...

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung ...

Cancer research saved my daughter’s life, and despite setbacks, we must support these efforts to ensure more lives are saved ...

DEVASTATED Nadia Sawalha fought back tears in an emotional video as she shared some heartbreaking news. Loose Women star ...

Ann Marie Rogers won a landmark victory to make the breast cancer drug Herceptin more widely available. Here, she explains what drove her. But others are asking if the treatment really lives up to ...

and in the US manufacturers of branded drugs have become adept at constructing patent defences to prevent competition. The latest Herceptin biosimilar is branded as Kanjinti (trastuzumab-anns ...

New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have ...

The six-month continuing resolution before Congress would cut $1.2 billion from the Pentagon's health research into deadly ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...